NAD+ Oral Supplement Pilot Intervention in Adult Females

Not Applicable

Recruiting

• Conditions: Cognitive Change; Inflammation; Neurodegenerative Diseases

• Registration Number: NCT06579209
• Lead Sponsor: University of Rhode Island

Brief Summary

The goal of this clinical trial is to learn if Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women who identify as Latina and are between the ages of 40-80. The main questions it aims to answer are:

Will executive function change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving the NAD+ to see if the results differ from those receiving the placebo.

Participants will:

Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-08
• Study First Submitted: 2024-08-28
• Study First Submitted QC: 2024-08-28
• Study First Posted: 2024-08-30
• Study Start: 2024-12-01
• Last Update Submitted: 2025-02-12
• Last Update Posted: 2025-02-17
• Primary Completion: 2025-05-01
• Study Completion: 2025-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

• Identify as Latina, have three or more adverse childhood experiences, and a BMI of 18.5 or above

Exclusion Criteria

• Those who are taking hormone medication, pregnant or breastfeeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Neurocognition	four weeks	NIH Toolkit Cognition Battery, Automated Neuropsychological Assessment Metrics
Neurodegenerative disease panel	four weeks	BDNF, Cathespin D, MPO, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, slCAM-1, sNCAM, sVCAM-1
Markers of systemic inflammation	four weeks	GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNFα

Trial Locations

Locations (2)

University of Rhode Island; 🇺🇸 Kingston, Rhode Island, United States

Independence Square, University of Rhode Island; 🇺🇸 Pawtucket, Rhode Island, United States